spironolactone has been researched along with Alloxan Diabetes in 41 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "En face analysis revealed that eplerenone treatment was unable to attenuate atherosclerosis as assessed by percentage lesion area quantitation in the aortae of these mice compared with untreated diabetic mice (diabetic, 10." | 7.75 | Eplerenone does not attenuate diabetes-associated atherosclerosis. ( Allen, TJ; Cooper, ME; Koh, PJ; Koitka, A, 2009) |
| "En face analysis revealed that eplerenone treatment was unable to attenuate atherosclerosis as assessed by percentage lesion area quantitation in the aortae of these mice compared with untreated diabetic mice (diabetic, 10." | 3.75 | Eplerenone does not attenuate diabetes-associated atherosclerosis. ( Allen, TJ; Cooper, ME; Koh, PJ; Koitka, A, 2009) |
| "Streptozotocin-induced renal fibrosis, PAI-1 expression, TGF-beta1 expression, and macrophage infiltration occur via mineralocorticoid receptor, and spironolactone ameliorates renal fibrosis presumably via the inhibition of macrophage infiltration, PAI-1 expression, and TGF-beta1 expression in streptozotocin-induced early diabetic injury." | 3.72 | Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. ( Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K, 2004) |
| "Eplerenone pretreatment reduced the arterial pressure, cardiac inotropy, and lusitropy." | 1.48 | Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. ( Agrawal, YO; Chandrayan, G; Goyal, SN; Mahajan, UB; Ojha, S; Patil, CR; Patil, PD, 2018) |
| "Type 1 diabetes was induced in female Wistar rats by a single tail vein injection of streptozotocin (STZ), and SPL was administrated daily by gavage, from days 3-21." | 1.46 | Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats. ( González-Ramírez, R; Molina-Jijón, E; Namorado-Tónix, C; Pedraza-Chaverri, J; Reyes, JL; Rodríguez-Muñoz, R, 2017) |
| "Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice." | 1.42 | Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus. ( Bruder-Nascimento, T; Cau, SB; Lopes, RA; Manzato, CP; Mestriner, FL; Montezano, AC; Neves, KB; Nguyen Dinh Cat, A; Silva, MA; Tostes, RC; Touyz, RM, 2015) |
| " Our results showed a marked increase in aortic malondialdehyde (MDA) level and upregulation of the catalytic NADPH oxidase subunit, NOX2 gene expression alongside reducing catalase enzyme capacity, and the serum nitric oxide (NO) bioavailability in diabetic rats." | 1.40 | Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. ( Adel, H; Khalifa, MM; Taye, A, 2014) |
| " There was a marked decrease in nitric oxide (NO) bioavailability and antioxidant enzyme capacity." | 1.40 | Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. ( El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014) |
| "We evaluated the effects of RU28318 (RU), a selective mineralocorticoid receptor (MR) antagonist, Captopril (Capt), an angiotensin converting enzyme inhibitor, and Losartan (Los), an angiotensin receptor blocker, alone or in combination with ischemia/reperfusion- (I/R-) induced cardiac dysfunction in hearts obtained from normal and diabetic rats." | 1.39 | RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. ( Akhtar, S; Al-Rashdan, I; Babiker, F; Benter, IF; Yousif, M, 2013) |
| " Eplerenone improves endothelial function by reducing superoxide formation and increasing NO bioavailability in diabetic rats." | 1.36 | Eplerenone improves vascular function and reduces platelet activation in diabetic rats. ( Bauersachs, J; Ertl, G; Flierl, U; Fraccarollo, D; Hildemann, SK; Schafer, A; Vogt, C; Widder, J, 2010) |
| "Tail flick latency, an index of hyperalgesia, was assessed by analgesiometer." | 1.35 | Ameliorative potential of spironolactone in diabetes induced hyperalgesia in mice. ( Bakshi, KS; Jaggi, AS; Khan, N; Singh, N, 2009) |
| "Spironolactone treatment for one week also resulted in a significant reduction in mean systolic blood pressure during the development of diabetic hypertension." | 1.31 | Effects of spironolactone on systolic blood pressure in experimental diabetic rats. ( Liu, YJ; Nakagawa, Y; Nakanishi, T; Ohzeki, T; Saegusa, H; Toya, K; Wang, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (24.39) | 29.6817 |
| 2010's | 27 (65.85) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Lyngsø, KS | 1 |
| Jensen, BL | 1 |
| Hansen, PBL | 1 |
| Dimke, H | 1 |
| Ghaffari, T | 1 |
| Moradi, N | 2 |
| Chamani, E | 2 |
| Ebadi, Z | 2 |
| Fadaei, R | 2 |
| Alizadeh-Fanalou, S | 1 |
| Yarahmadi, S | 1 |
| Fallah, S | 2 |
| Kazemi Fard, T | 1 |
| Balochnejadmojarrad, T | 1 |
| Balogh, DB | 2 |
| Molnar, A | 2 |
| Hosszu, A | 2 |
| Lakat, T | 2 |
| Hodrea, J | 2 |
| Szabo, AJ | 2 |
| Lenart, L | 2 |
| Fekete, A | 2 |
| Molina-Jijón, E | 1 |
| Rodríguez-Muñoz, R | 1 |
| González-Ramírez, R | 1 |
| Namorado-Tónix, C | 1 |
| Pedraza-Chaverri, J | 1 |
| Reyes, JL | 1 |
| Vranic, A | 1 |
| Simovic, S | 1 |
| Ristic, P | 1 |
| Nikolic, T | 1 |
| Stojic, I | 1 |
| Srejovic, I | 1 |
| Zivkovic, V | 1 |
| Jakovljevic, V | 1 |
| Djuric, D | 1 |
| Mahajan, UB | 1 |
| Patil, PD | 1 |
| Chandrayan, G | 1 |
| Patil, CR | 1 |
| Agrawal, YO | 1 |
| Ojha, S | 1 |
| Goyal, SN | 1 |
| Koszegi, S | 1 |
| Szkibinszkij, E | 1 |
| Sparding, N | 1 |
| Genovese, F | 1 |
| Wagner, L | 1 |
| Vannay, A | 1 |
| Liu, W | 1 |
| Gong, W | 1 |
| He, M | 1 |
| Liu, Y | 1 |
| Yang, Y | 1 |
| Wang, M | 1 |
| Wu, M | 1 |
| Guo, S | 1 |
| Yu, Y | 1 |
| Wang, X | 1 |
| Sun, F | 1 |
| Li, Y | 1 |
| Zhou, L | 1 |
| Qin, S | 1 |
| Zhang, Z | 1 |
| Dong, D | 1 |
| Fan, TT | 1 |
| Ji, YS | 1 |
| Yu, JY | 1 |
| Wu, S | 1 |
| Zhang, L | 1 |
| López-Rubalcava, C | 1 |
| Paez-Martinez, N | 1 |
| Oikawa, J | 1 |
| Patel, BM | 2 |
| Kakadiya, J | 1 |
| Goyal, RK | 2 |
| Mehta, AA | 2 |
| Bhadada, SV | 1 |
| Benter, IF | 1 |
| Babiker, F | 1 |
| Al-Rashdan, I | 1 |
| Yousif, M | 1 |
| Akhtar, S | 1 |
| Nagatomo, Y | 1 |
| Meguro, T | 1 |
| Ito, H | 1 |
| Koide, K | 1 |
| Anzai, T | 1 |
| Fukuda, K | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Zakrzeska, A | 1 |
| Gromotowicz-Popławska, A | 1 |
| Szemraj, J | 1 |
| Szoka, P | 1 |
| Kisiel, W | 1 |
| Purta, T | 1 |
| Kasacka, I | 1 |
| Chabielska, E | 1 |
| Adel, H | 1 |
| Taye, A | 2 |
| Khalifa, MM | 2 |
| Hofni, A | 1 |
| El-Moselhy, MA | 1 |
| Silva, MA | 1 |
| Cau, SB | 1 |
| Lopes, RA | 1 |
| Manzato, CP | 1 |
| Neves, KB | 1 |
| Bruder-Nascimento, T | 1 |
| Mestriner, FL | 1 |
| Montezano, AC | 1 |
| Nguyen Dinh Cat, A | 1 |
| Touyz, RM | 1 |
| Tostes, RC | 1 |
| Mayyas, F | 1 |
| Alzoubi, KH | 1 |
| Bonyan, R | 1 |
| Taira, M | 1 |
| Toba, H | 2 |
| Murakami, M | 1 |
| Iga, I | 1 |
| Serizawa, R | 2 |
| Murata, S | 1 |
| Kobara, M | 2 |
| Nakata, T | 2 |
| Koh, PJ | 1 |
| Koitka, A | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Khan, N | 1 |
| Bakshi, KS | 1 |
| Jaggi, AS | 1 |
| Singh, N | 1 |
| Noll, C | 1 |
| Messaoudi, S | 1 |
| Milliez, P | 1 |
| Samuel, JL | 1 |
| Delcayre, C | 1 |
| Janel, N | 1 |
| Goyal, BR | 1 |
| Solanki, N | 1 |
| Schafer, A | 1 |
| Vogt, C | 1 |
| Fraccarollo, D | 1 |
| Widder, J | 1 |
| Flierl, U | 1 |
| Hildemann, SK | 1 |
| Ertl, G | 1 |
| Bauersachs, J | 1 |
| Lin, S | 1 |
| Li, D | 1 |
| Jia, J | 1 |
| Zheng, Z | 1 |
| Jia, Z | 1 |
| Shang, W | 1 |
| Mitani, T | 1 |
| Takahashi, T | 1 |
| Imai, N | 1 |
| Wang, J | 1 |
| Mavrakanas, TA | 1 |
| Cheva, A | 1 |
| Kallaras, K | 1 |
| Karkavelas, G | 1 |
| Mironidou-Tzouveleki, M | 1 |
| Toyonaga, J | 1 |
| Tsuruya, K | 1 |
| Ikeda, H | 1 |
| Noguchi, H | 1 |
| Yotsueda, H | 1 |
| Fujisaki, K | 1 |
| Hirakawa, M | 1 |
| Taniguchi, M | 1 |
| Masutani, K | 1 |
| Iida, M | 1 |
| Lian, M | 1 |
| Hewitson, TD | 1 |
| Wigg, B | 1 |
| Samuel, CS | 1 |
| Chow, F | 1 |
| Becker, GJ | 1 |
| Takata, H | 1 |
| Takeda, Y | 1 |
| Zhu, A | 1 |
| Cheng, Y | 1 |
| Yoneda, T | 1 |
| Demura, M | 1 |
| Yagi, K | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| Pessôa, BS | 1 |
| Peixoto, EB | 1 |
| Papadimitriou, A | 1 |
| Lopes de Faria, JM | 1 |
| Lopes de Faria, JB | 1 |
| Zhou, Q | 1 |
| Liu, K | 1 |
| Wu, H | 1 |
| Chen, L | 1 |
| Pouranan, V | 1 |
| Yuan, M | 1 |
| Xiao, Z | 1 |
| Peng, W | 1 |
| Xiang, A | 1 |
| Tang, R | 1 |
| Zhang, W | 1 |
| Verma, S | 1 |
| Yuen, VG | 1 |
| Badiwala, M | 1 |
| Anderson, TJ | 1 |
| McNeill, JH | 1 |
| Fujisawa, G | 1 |
| Okada, K | 1 |
| Muto, S | 1 |
| Fujita, N | 1 |
| Itabashi, N | 1 |
| Kusano, E | 1 |
| Ishibashi, S | 1 |
| Guo, C | 1 |
| Martinez-Vasquez, D | 1 |
| Mendez, GP | 1 |
| Toniolo, MF | 1 |
| Yao, TM | 1 |
| Oestreicher, EM | 1 |
| Kikuchi, T | 1 |
| Lapointe, N | 1 |
| Pojoga, L | 1 |
| Williams, GH | 1 |
| Ricchiuti, V | 1 |
| Adler, GK | 1 |
| Yuan, J | 1 |
| Jia, R | 1 |
| Bao, Y | 1 |
| Liu, YJ | 1 |
| Nakagawa, Y | 1 |
| Toya, K | 1 |
| Wang, Y | 1 |
| Saegusa, H | 1 |
| Nakanishi, T | 1 |
| Ohzeki, T | 1 |
| Miric, G | 1 |
| Dallemagne, C | 1 |
| Endre, Z | 1 |
| Margolin, S | 1 |
| Taylor, SM | 1 |
| Brown, L | 1 |
| Genes, SG | 1 |
41 other studies available for spironolactone and Alloxan Diabetes
| Article | Year |
|---|---|
Endothelial mineralocorticoid receptor ablation confers protection towards endothelial dysfunction in experimental diabetes in mice.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Mice; Mice, Knockout; Mineralocorticoid Recep | 2022 |
Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33.
Topics: Animals; ATP Binding Cassette Transporter 1; Captopril; Diabetes Mellitus, Experimental; Diabetic Ne | 2022 |
Captopril and Spironolactone Can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting microRNA-192 and microRNA-29a/b/c.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Urea Nitrogen; Captopril; Creatinine; Diabete | 2019 |
Antidepressant effect in diabetes-associated depression: A novel potential of RAAS inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antidepressive Agents; Antihypertensive Agents; B | 2020 |
Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats.
Topics: Aldosterone; Animals; Claudin-4; Claudins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats.
Topics: Animals; Coronary Circulation; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; He | 2017 |
Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats.
Topics: Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Eplerenone; Male; Myocardial Reperfusi | 2018 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Lin | 2019 |
Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Inflammation; Male; Myocardium; | 2018 |
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Autophagy; Beclin-1; Diabetes Me | 2019 |
Blockade of corticosteroid receptors induces anxiolytic-like effects in streptozotocin-induced diabetic mice, and synergizes with diazepam.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Blood Glucose; Diabetes Mellitus, Experimental; Diazepam; Dos | 2013 |
Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats.
Topics: Animals; Cardiovascular Diseases; Cytoprotection; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2013 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diab | 2013 |
Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Eplerenone; Male; Mice; Mice, K | 2014 |
Eplerenone reduces arterial thrombosis in diabetic rats.
Topics: Animals; Carotid Arteries; Diabetes Mellitus, Experimental; Eplerenone; Hemostasis; Interleukins; Ma | 2015 |
Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Animals; Antioxidants; Aorta; Diabetes Mellitus, Experimental; Diabetic Angiop | 2014 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabete | 2014 |
Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2 diabetes mellitus.
Topics: Aldosterone; Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Collagen; Diabetes Me | 2015 |
The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes.
Topics: Aldosterone; Animals; Blood Pressure; Catalase; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Experim | 2017 |
Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Topics: Animals; Collagen Type I; Collagen Type IV; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Experimenta | 2008 |
Eplerenone does not attenuate diabetes-associated atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Diabetes Mellitus, Experimental; Enzyme | 2009 |
Ameliorative potential of spironolactone in diabetes induced hyperalgesia in mice.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Hyperalgesia; Male; Mice; Nitric Oxide; Spironolac | 2009 |
Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice.
Topics: Animals; Aryldialkylphosphatase; Diabetes Mellitus, Experimental; Eplerenone; Mice; Spironolactone | 2010 |
Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes.
Topics: Animals; Blood; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Carrier Protein | 2009 |
Eplerenone improves vascular function and reduces platelet activation in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelium, Vascular; E | 2010 |
Spironolactone ameliorates podocytic adhesive capacity via restoring integrin alpha 3 expression in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Integrin alpha3beta1; Male; Po | 2010 |
Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropat | 2010 |
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Creatinine; Diabetes Mellitus, Experimental; Diab | 2010 |
Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Hyperglycemia; Male; Mineralocorticoid | 2011 |
Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen Type IV; Diabetes Mellitus, Experi | 2012 |
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2012 |
Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat.
Topics: Animals; Antioxidants; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; DNA Dama | 2012 |
Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats.
Topics: Acute Kidney Injury; Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2012 |
Working heart function in diabetes is not improved by spironolactone treatment.
Topics: Animals; Atrial Function, Left; Diabetes Mellitus, Experimental; Diastole; In Vitro Techniques; Male | 2003 |
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hypertrophy; Immunohisto | 2004 |
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2006 |
Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glutathione Peroxida | 2007 |
Effects of spironolactone on systolic blood pressure in experimental diabetic rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Corticosterone; Diabetes Mellitus, Expe | 2000 |
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calci | 2001 |
[Corticosteroids and the liver].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Animals; Biotransformation; Diabetes Mellitus, Experimental | 1977 |